Novus Advisors LLC Takes Position in Johnson & Johnson (NYSE:JNJ)

Novus Advisors LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,684 shares of the company's stock, valued at approximately $822,000.

Other institutional investors also recently made changes to their positions in the company. Wealth Group Ltd. acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $213,000. Swedbank AB increased its holdings in shares of Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock worth $358,980,000 after purchasing an additional 111,570 shares during the period. Walkner Condon Financial Advisors LLC raised its position in shares of Johnson & Johnson by 4.4% in the third quarter. Walkner Condon Financial Advisors LLC now owns 2,843 shares of the company's stock valued at $461,000 after buying an additional 121 shares in the last quarter. Bridgewater Advisors Inc. boosted its stake in shares of Johnson & Johnson by 34.0% in the third quarter. Bridgewater Advisors Inc. now owns 31,286 shares of the company's stock valued at $5,009,000 after buying an additional 7,934 shares during the period. Finally, David J Yvars Group bought a new position in Johnson & Johnson during the 3rd quarter worth $205,000. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. Citigroup cut their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Tuesday, January 28th. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Leerink Partners cut their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Finally, Bank of America increased their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research report on Wednesday. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $171.33.

Remove Ads

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark A. Weinberger bought 1,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.6 %

JNJ traded up $0.98 during midday trading on Friday, hitting $166.81. 9,636,645 shares of the company were exchanged, compared to its average volume of 7,032,060. The firm has a market capitalization of $401.61 billion, a P/E ratio of 25.08, a P/E/G ratio of 2.56 and a beta of 0.47. The firm's 50 day moving average price is $152.95 and its 200-day moving average price is $156.28. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the prior year, the business posted $2.29 earnings per share. The firm's revenue was up 5.3% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.